AURORA SPINE CORP - ASAPF STOCK NEWS

Aurora Spine Corporation (OTCQB: ASAPF) announced the successful initial surgeries of its FDA-approved SiLO TFX™ MIS Sacroiliac Joint Fixation Device, with over a dozen patients receiving the implant. The SiLO TFX is designed for sacroiliac joint fusion, targeting conditions like joint disruptions and degenerative sacroiliitis. With a significant market potential, 30 million Americans suffer from lower back pain, with 4.7 million experiencing SI joint pain. The device simplifies the implantation process, aligning with existing non-surgical treatment methods. CEO Trent Northcutt expressed optimism regarding the device's capability to enhance surgical outcomes, signaling a forthcoming full market launch by mid-year. Surgeons have praised the device's seamless technique and potential for superior results.

Aurora Spine Corporation (TSXV:ASG, OTCQB:ASAPF) announced that its DEXA Technology will be showcased at the AANS Annual Scientific Meeting from April 21-24, 2023. Dr. Sebastian Koga will present findings on the DEXA-C device, demonstrating its 43% lower risk of subsidence compared to standard PEEK cages. Subsidence is a complication in spinal surgeries where vertebral discs sink around implants, which can lead to instability. Dr. Koga emphasized that DEXA-C's design, which matches patient bone density, enhances performance in older patients with low bone density. Aurora's President, Trent Northcutt, expressed excitement about the device's strength and superior performance during the presentation.

Aurora Spine has announced the approval for a multicenter study of its DEXA-C™ Cervical Interbody System, aimed at improving spinal surgery outcomes. Seven sites have been selected, three are pending approval, with patient enrollment anticipated soon. The clinical trial will involve 80 subjects, assessing the system's effectiveness in anterior cervical discectomy and fusion procedures. Aurora's patented DEXA™ technology targets varying bone densities to enhance fusion success. Key outcomes will be monitored at multiple post-surgery intervals, focusing on fusion assessment and patient-reported results.

Aurora Spine Corporation (OTCQB: ASAPF) announced IRB approval for a multicenter study of its DEXA-C Cervical Interbody System, aimed at anterior cervical interbody fusion in patients with degenerative disc disease. This system utilizes Aurora's patented DEXA technology, designed to match implants with a patient’s bone density. The study will involve 10 sites across the U.S. with data from at least 80 subjects. Initial beta-testing responses have been positive, with researchers optimistic about improved surgical outcomes. The study will evaluate fusion success and subsidence metrics at various follow-up intervals.

Aurora Spine Corporation (TSXV:ASG, OTCQB:ASAPF) will present at the Planet MicroCap Showcase: VIRTUAL 2022 on December 7, 2022, at 10:00 AM EST. President and CEO Trent Northcutt and CFO Chad Clouse will lead the session, followed by a Q&A. Attendees can register for 1on1 meetings or view the presentation via the conference's online platform. Aurora Spine focuses on innovative, minimally invasive spinal devices aimed at improving surgical outcomes. For more information, visit aurora-spine.com.

Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will release its third-quarter financial results for the period ended September 30, 2022, on November 21, 2022. Following the release, management will hold a conference call at 11:00 a.m. ET to discuss the results, which can be accessed via phone or a live webcast. The replay of this call will be available until November 28, 2022. Aurora Spine focuses on innovative, minimally invasive spinal implant technologies aimed at improving surgical outcomes.

Aurora Spine Corporation recently announced positive interim results from the REFINE Study on its ZIP™ MIS Interspinous Fusion System. The study, involving 54 patients, showed that 82% of participants experienced improvement after 3 months, with 65% reporting significant enhancements in pain and function. This data, published in Pain and Therapy, highlights the device's effectiveness and safety. Conducted by 11 doctors, the study aims to address the significant unmet need in treating lumbar spinal stenosis. Further results are expected at the 12-month follow-up.

Aurora Spine Corporation is set to participate in the 2022 North American Spine Society (NASS) Annual Meeting from October 12-15 in Chicago. The company will showcase innovative products like the newly FDA cleared SiLO TFX SI Fusion System, designed for sacroiliac joint fusion surgery, and DEXA Technology products for spinal procedures. CEO Trent Northcutt highlighted the importance of the event for showcasing their advancements and growing their sales pipeline, anticipating a strong momentum for the remainder of fiscal 2022 and into 2023.

Aurora Spine Corporation (OTCQB: ASAPF) has been awarded the 2022 Annual Spine Technology Award for its innovative DEXA Technology™ Bone Density-Matched Interbody Implants. Recognized by RRY Publications LLC and Orthopedics this Week, this technology adjusts spinal implants to match patients’ bone density, enhancing surgical outcomes. The award will be presented at the 37th Annual Meeting of the North American Spine Society in Chicago. Aurora Spine emphasizes that DEXA Technology™ represents a significant advancement in spinal implants, merging conventional machining, 3D printing, and additive manufacturing.